Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP395 in chronic obstructive pulmonary disease
2021-005787-22Phase 2Completed
- Sponsor
- EpiEndo Pharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing EP395 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2022; status: completed.
02
Drugs
glasmacinal
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2021-005787-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005787-22.